



European Network of Paediatric Research at the European Medicines Agency



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Action points

---

Mark Turner



# Challenges

Identifying and attributing value creation

Multiple pathways to success

- Stimulus for network development
- Legacy of previous achievements

Efficiency: time and cost

Predictability

Learning from experience

Global coordination

## Action points: Working Groups 1

### **Training of Research nurses**

Core curriculum for research nurses

Gather examples of good practice

### **Ethics**

Ongoing update of ethics toolkit

Work with EUREC: develop agenda for transnational harmonisation for implementation nationally

### **YPAG**

Business Case

Interface between EYPAGnet and disease-specific patient groups

## Action points: Working Groups 2

### **Industry-network-regulatory interactions**

Pilot of consultation process (implementation and survey)  
[beneficial to integrate with IMI2 project]

### **Antibiotics**

Publish review and follow-up

## Other action points

### **Academia**

Pilot of consultation process (implementation and survey)

### **European Reference Networks**

Joint working: close dialogue with ERN CG Research Group

- Contact points
- Facilitating paediatric development of medicines developed for adult rare diseases

### **International collaboration**

Discussions between global networks (EnprEMA, iACT, KIDSCAN, China, PTNA etc.)

# Thank you for your attention

## Further information

---

**European Network of Paediatric Research at the European Medicines Agency**  
([Enpr-EMA](#))

### **European Medicines Agency**

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

**Send a question via our website** [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact)

Follow us on  **@EMA\_News**